High released lactate by epicardial fat from coronary artery disease patients is reduced by dapagliflozin treatment

Dapagliflozin, a sodium-glucose co-transporter 2 inhibitor, improves glucose uptake by epicardial adipose tissue (EAT). However, its metabolism might raise the lactate production and acidosis under hypoxia conditions, i.e. coronary artery disease (CAD), or lipogenesis and, in consequence, expand adi...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Atherosclerosis 2020-01, Vol.292, p.60-69
Hauptverfasser:	Couselo-Seijas, Marinela, Agra-Bermejo, Rosa María, Fernández, Angel Luis, Martínez-Cereijo, José Manuel, Sierra, Juan, Soto-Pérez, Maeve, Rozados-Luis, Adriana, González-Juanatey, José Ramón, Eiras, Sonia
Format:	Artikel
Sprache:	eng
Schlagworte:	Adipose Tissue - drug effects Adipose Tissue - metabolism Benzhydryl Compounds - pharmacology Coronary artery disease Coronary Artery Disease - metabolism Epicardial fat metabolism Glucose - metabolism Glucosides - pharmacology Humans Lactic Acid - metabolism Pericardium - drug effects Pericardium - metabolism SGLT2 inhibitor Sodium-Glucose Transport Proteins - pharmacology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!